中国血液净化

中国血液净化 ›› 2023, Vol. 22 ›› Issue (1): 52-55.doi: 10.3969/j.issn.1671-4091.2023.01.012

• 综述 • 上一篇    下一篇

钙卫蛋白作为腹膜透析相关腹膜纤维化诊疗新靶点的探讨

阮怡霖    徐  天    任  红   

  1. 200025 上海，1上海交通大学医学院附属瑞金医院肾内科
  • 收稿日期:2022-06-13 修回日期:2022-08-21 出版日期:2023-01-12 发布日期:2023-01-12
  • 通讯作者: 任红 E-mail:renhong66@126.com

Investigation on calprotectin as a new target for the diagnosis and treatment of peritoneal dialyis-related peritoneal fibrosis

RUAN Yi-lin, XU Tian, REN Hong   

  1. Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
  • Received:2022-06-13 Revised:2022-08-21 Online:2023-01-12 Published:2023-01-12
  • Contact: 200025 上海，1上海交通大学医学院附属瑞金医院肾内科 E-mail:renhong66@126.com

PDF

117

摘要： 钙卫蛋白(S100A8/A9)属于S100家族中的Ca2+结合蛋白，具有广泛的生物学活性，可以作为多种疾病的生物标志物。腹膜透析(peritoneal dialysis,PD)相关性腹膜纤维化(peritoneal fibrosis，PF)是PD患者中常见的并发症之一。近年来，S100A8/A9致纤维化作用也逐渐被证实，前期研究证明S100A8/A9在PF时显著上调，抑制PF后表达下降。本文主要围绕S100A8/A9作为PF诊疗新靶点的前景探讨。

关键词: 钙卫蛋白, 腹膜纤维化, 腹膜透析

Abstract: Calprotectin (S100A8/A9) is a Ca2+ binding protein in the S100 protein family, having a wide range of biological activities and serving as a biomarker for many diseases. Peritoneal dialysis-related peritoneal fibrosis is one of the common complications in peritoneal dialysis (PD) patients. Many studies have recently proved that S100A8/A9 plays an important part in the development of peritoneal fibrosis. Our previous study also confirms that S100A8/A9 is up-regulated in peritoneal fibrosis and down-regulated after inhibition of peritoneal fibrosis. This article discusses the prospect of S100A8/A9 as a new target for the diagnosis and treatment of peritoneal fibrosis.

Key words: S100A8/A9, Peritoneal fibrosis, Peritoneal dialysis

中图分类号: